Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 69


Altered expression of genes involved in ganglioside biosynthesis in substantia nigra neurons in Parkinson's disease.

Schneider JS.

PLoS One. 2018 Jun 14;13(6):e0199189. doi: 10.1371/journal.pone.0199189. eCollection 2018.


Caffeine, creatine, GRIN2A and Parkinson's disease progression.

Simon DK, Wu C, Tilley BC, Lohmann K, Klein C, Payami H, Wills AM, Aminoff MJ, Bainbridge J, Dewey R, Hauser RA, Schaake S, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wei P, Wong PS, Yang T.

J Neurol Sci. 2017 Apr 15;375:355-359. doi: 10.1016/j.jns.2017.02.032. Epub 2017 Feb 17.


Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1.

Wills AA, Elm JJ, Ye R, Chou KL, Parashos SA, Hauser RA, Bodis-Wollner I, Hinson VK, Christine CW, Schneider JS; NINDS NET-PD Investigators.

Parkinsonism Relat Disord. 2016 Dec;33:127-133. doi: 10.1016/j.parkreldis.2016.10.005. Epub 2016 Oct 8.


Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease.

Schneider JS, Seyfried TN, Choi HS, Kidd SK.

PLoS One. 2015 Dec 2;10(12):e0143351. doi: 10.1371/journal.pone.0143351. eCollection 2015.


Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine.

Simon DK, Wu C, Tilley BC, Wills AM, Aminoff MJ, Bainbridge J, Hauser RA, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wong PS.

Clin Neuropharmacol. 2015 Sep-Oct;38(5):163-9. doi: 10.1097/WNF.0000000000000102.


GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding.

Schneider JS, Cambi F, Gollomp SM, Kuwabara H, Brašić JR, Leiby B, Sendek S, Wong DF.

J Neurol Sci. 2015 Sep 15;356(1-2):118-23. doi: 10.1016/j.jns.2015.06.028. Epub 2015 Jun 16.


Relationship between Motor Symptoms, Cognition, and Demographic Characteristics in Treated Mild/Moderate Parkinson's Disease.

Schneider JS, Sendek S, Yang C.

PLoS One. 2015 Apr 23;10(4):e0123231. doi: 10.1371/journal.pone.0123231. eCollection 2015.


Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.

Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB Jr, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Pérez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM.

JAMA. 2015 Feb 10;313(6):584-93. doi: 10.1001/jama.2015.120.


No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial.

Umeh CC, Pérez A, Augustine EF, Dhall R, Dewey RB Jr, Mari Z, Simon DK, Wills AM, Christine CW, Schneider JS, Suchowersky O.

PLoS One. 2014 Dec 8;9(12):e112287. doi: 10.1371/journal.pone.0112287. eCollection 2014.


Retinal pathology detected by optical coherence tomography in an animal model of Parkinson's disease.

Schneider JS, Ault ME, Anderson DW.

Mov Disord. 2014 Oct;29(12):1547-51. doi: 10.1002/mds.25974. Epub 2014 Jul 28.


The neurobiological basis of cognitive impairment in Parkinson's disease.

Halliday GM, Leverenz JB, Schneider JS, Adler CH.

Mov Disord. 2014 Apr 15;29(5):634-50. doi: 10.1002/mds.25857. Review.


Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model.

Schneider JS, Pioli EY, Jianzhong Y, Li Q, Bezard E.

Mov Disord. 2013 May;28(5):663-7. doi: 10.1002/mds.25258. Epub 2012 Dec 12.


A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients.

Schneider JS, Gollomp SM, Sendek S, Colcher A, Cambi F, Du W.

J Neurol Sci. 2013 Jan 15;324(1-2):140-8. doi: 10.1016/j.jns.2012.10.024. Epub 2012 Nov 28.


Behavioral toxicology of cognition: extrapolation from experimental animal models to humans: behavioral toxicology symposium overview.

Paule MG, Green L, Myerson J, Alvarado M, Bachevalier J, Schneider JS, Schantz SL.

Neurotoxicol Teratol. 2012 Mar;34(2):263-73. doi: 10.1016/ Epub 2012 Jan 28.


Attention, executive functioning and memory in normal aged rhesus monkeys.

Zeamer A, Decamp E, Clark K, Schneider JS.

Behav Brain Res. 2011 May 16;219(1):23-30. doi: 10.1016/j.bbr.2010.12.021. Epub 2010 Dec 17.


Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.

Schneider JS, Elm JJ, Parashos SA, Ravina BM, Galpern WR; NET-PD Investigators.

Parkinsonism Relat Disord. 2010 Sep;16(8):507-12. doi: 10.1016/j.parkreldis.2010.06.001. Epub 2010 Jul 2.


GM1 ganglioside in Parkinson's disease: Results of a five year open study.

Schneider JS, Sendek S, Daskalakis C, Cambi F.

J Neurol Sci. 2010 May 15;292(1-2):45-51. doi: 10.1016/j.jns.2010.02.009. Epub 2010 Mar 5.


Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats.

Cai J, Yang M, Poremsky E, Kidd S, Schneider JS, Iacovitti L.

Stem Cells Dev. 2010 Jul;19(7):1017-23. doi: 10.1089/scd.2009.0319.


Repeatable battery for assessment of neuropsychological status in early Parkinson's disease.

Yang C, Garrett-Mayer E, Schneider JS, Gollomp SM, Tilley BC.

Mov Disord. 2009 Jul 30;24(10):1453-60. doi: 10.1002/mds.22552.


Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model.

Decamp E, Schneider JS.

Brain Res. 2009 Mar 25;1262:109-14. doi: 10.1016/j.brainres.2009.01.028. Epub 2009 Feb 7.

Supplemental Content

Loading ...
Support Center